Combined pCPA and muscarinic antagonist treatment produces a deficit in rat water maze acquisition

Pharmacol Biochem Behav. 1996 Sep;55(1):61-5. doi: 10.1016/0091-3057(96)00049-4.

Abstract

A 3-day treatment with p-chlorophenylalanine (pCPA, 100 mg/kg/day) produced a significant decrease (63-89%) in 5-HT levels in both the hippocampus and the cortex of rats, while noradrenaline, adrenaline, and dopamine levels were unaffected. Treatment with pCPA alone did not affect the acquisition of a spatial learning task in the water maze. Treatment with low doses of either scopolamine (0.25 mg/kg) or atropine (10 mg/kg) was also insufficient to cause a significant impairment of water maze acquisition. However, a combined treatment of a 3-day pCPA regimen with the low dose of atropine or scopolamine produced a significant deficit in the acquisition of a water maze task.

MeSH terms

  • Animals
  • Atropine / pharmacology
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Chromatography, High Pressure Liquid
  • Depression, Chemical
  • Dopamine / metabolism
  • Dose-Response Relationship, Drug
  • Electrochemistry
  • Fenclonine / pharmacology*
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Male
  • Maze Learning / drug effects*
  • Muscarinic Antagonists / pharmacology*
  • Norepinephrine / metabolism
  • Rats
  • Scopolamine / pharmacology
  • Serotonin / metabolism
  • Serotonin Agents / pharmacology*

Substances

  • Muscarinic Antagonists
  • Serotonin Agents
  • Serotonin
  • Atropine
  • Scopolamine
  • Fenclonine
  • Dopamine
  • Norepinephrine